Please assess the completion status of the following clinical trial:

Trial Title: ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Biopsy proven nasopharyngeal carcinoma, with detectable pretreatment plasma EBV DNA~2. Have detectable plasma EBV DNA at the end of (+/- 1 week) curative radiotherapy or chemoradiotherapy (radiation dose \> 66Gy), determined by the central lab~3. No clinical evidence of persistent loco-regional disease~4. No evidence of distant metastasis, based upon skeletal scintigraphy, chest X-ray examination, and liver ultrasound or other appropriate workup (e.g., CT, MRI or positron emission tomography (PET)/CT\]) within 21 days prior to registration~5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1~6. Anticipated survival \>= 3 months~7. Absolute neutrophil count (ANC) \>= 1,500 cells/mm\^3~8. Platelets \> 80,000 cells/mm\^3~9. Hemoglobin \>= 8.0 g/dl (no transfusion within the last 14 days)~10. Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN)~11. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =\< 2.5 x institutional ULN~12. Creatinine clearance (CC) \>= 50 ml/min estimated by Cockcroft-Gault formula~Exclusion Criteria:~1. Patients with stage III-IV disease (American Joint Committee On Cancer/Union for International Cancer Control 7th) and no contraindication to chemotherapy that didn't receive platinum based concurrent chemotherapy during radiation~2. Patients with tumor possibly invaded main vessels (e.g. encasement of the internal jugular artery/vein) at diagnosis; or tumor that, in the judgment of the investigator, likely to invade main vessels and cause life-threatening hemorrhage events during study~3. History of serious hemorrhage events or grade 3 or higher hemorrhage within 4 weeks prior to registration~4. Hypertension that couldn't be well controlled with single medication; unstable angina; angina diagnosed within the last 3 months; myocardial infarction within the last 6 months; cardiac arrhythmia that need long-term medication; grade 2 or higher cardiac dysfunction (NYHA)~5. Proteinuria~6. Coagulation dysfunction or predisposition to hemorrhage; on treatment of anticoagulation medication or vitamin K antagonist; low dose warfarin (1mg po qd) or aspirin (less than 100mg daily) were permitted as long as the international normalized ratio (INR) = \< 1.5~7. Thrombosis within the last 1 year, except cured vein thrombosis related to vein indwelling catheter~8. Unhealed bone fracture or chronic unhealed wound~9. Illness that would interfere with oral medication, including dysphagia, chronic diarrhea, or ileus~10. Pregnant or lactating women~11. Women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception during and within 6 months after study~12. Current drug abuse or mentally disabled~13. History of congenital or acquired immune deficiency disease or organ transplantation~14. Major medical illness, which in the investigator's opinion would endanger the patients or interfere with the completion of therapy and follow up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Apatinib (Type: EXPERIMENTAL): In the phase IIb part of this trial, patients in this arm will take oral apatinib until disease progression, intolerable toxicity, death or to a maximum of 2 years.
- Placebo (Type: PLACEBO_COMPARATOR): In the phase IIb part of this trial, patients in this arm will take oral placebo until disease progression, intolerable toxicity, death or to a maximum of 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).